News this week concerning patients taking taking an experimental diabetes pill, who had more breast and bladder cancers than those on a standard drug.
In all the clinical programs, nine breast cancers and nine bladder cancers were seen among 5,478 patients taking the drug, dapagliflozin, compared with one breast and one bladder cancer among the 3,156 in control groups, Bristol-Myers and AstraZeneca have both said. Importantly, there was no imbalance in overall cancer risk, the companies said. Source here.
